Browsing Tag
Stock Market
39 posts
Home Depot (NYSE: HD) stock drops sharply as earnings outlook and housing headwinds weigh on sentiment
Home Depot stock dropped 8.8% in five days despite steady Q3 sales and AI rollout. Find out what’s driving investor sentiment in 2025.
Texas Roadhouse to open 35 new restaurants in 2026 amid 7 % commodity inflation
Texas Roadhouse targets 35 new restaurants in 2026 while managing 7 percent commodity inflation and strengthening beverage strategy to support margins.
Qualcomm’s Arduino acquisition: Can it redefine the developer ecosystem and boost investor confidence?
Find out how Qualcomm’s acquisition of Arduino could reshape the global developer ecosystem and strengthen its edge AI strategy in 2025.
Inside Algorhythm’s 10.1m share registration: could investor sentiment turn bearish after the filing?
Algorhythm Holdings (NASDAQ: RIME) registers 10.1 million shares for resale. Find out what this insider move means for investors and market sentiment.
Markets are calm for now — but here’s why a long U.S. shutdown could jolt Wall Street
The U.S. government shutdown has already begun. Will it rattle Wall Street or will markets remain calm as history suggests? Here’s what investors should know.
Microsoft in Trump’s crosshairs: What’s behind the demand to fire global affairs chief Lisa Monaco
President Trump demands Microsoft fire Lisa Monaco over national security claims, sparking political tension and investor caution. Find out what this means today.
Palantir’s stunning AI rally hits a wall — is this the start of a bigger reset?
Palantir’s stock slump highlights rising concerns over AI valuations and investor sentiment. Find out why the rally is under scrutiny and what comes next.
Harmony Gold Mining sees strong stock gains amid rising gold prices and strategic expansion
Harmony Gold Mining stock surges amid rising gold prices and strategic expansion into copper. Find out why investors are optimistic about its future.
Novartis wins FDA approval for Fabhalta, the first treatment for C3 glomerulopathy
Novartis secures FDA approval for Fabhalta, the first-ever treatment for C3G. Find out how this breakthrough impacts patients and investors.
UiPath shares tumble as revenue guidance misses market expectations
UiPath Inc. (NYSE: PATH) saw its stock plunge following a weaker-than-expected revenue outlook for the upcoming fiscal year,…